Nirmatrelvir-Ritonavir Reduced Mortality in Hospitalized Patients with COVID-19 During the Omicron Outbreak: Real-World Evidence from Beijing.

Yi ZhangXinrui WangChong HuangHui YangChunguo JiangXiaojia YuJun HongYi ZhangYushu WangRui ZhaoZhuoling AnZhao-Hui Tong

Published in: Infection and drug resistance (2024)

We found significantly reduced all-cause mortality in the nirmatrelvir-ritonavir group, particularly in elderly patients who were incompletely vaccinated. Future randomized controlled studies are needed to validate our findings.

Keyphrases

double blind
antiretroviral therapy
open label
air pollution
cardiovascular events
placebo controlled
current status
particulate matter
phase ii
community dwelling
case control
type diabetes